Instruction for use: Abergin

Dosage form: Substance-powder; Tablets

Active substance: Bromocriptine*

ATX

N04BC01 Bromocriptine

Pharmacological group:

Dopamine receptor agonist [Dophaminomimetics]

The nosological classification (ICD-10)

D24 Benign neoplasm of breast: Benign neoplasm of mammary gland; Benign mammary gland disease; Neoplastic processes in the mammary gland; Tumors of the mammary glands; Papilloma of the ducts of the mammary gland

D35.2 Benign neoplasm of pituitary gland: Pituitary adenoma; Prolactinomas; Macro-prolaktinoma; Microprolactinoma; Prolactinoma; Somatoliberinoma; Aumada del Castillo Syndrome Tumors of the pituitary and suprasellar region

E22.1 Hyperprolactinaemia: Hyperprolactinemia medication; Hyperprolactinaemia with infertility; Hyperprolactinemia in men; Hyperproduction of prolactin; Idiopathic hyperprolactinemia; Chiari-Frommel Syndrome; Forbes-Albright Syndrome; Tumor galactorrhea; Argonsa del Castillo Syndrome; Forbes-Albright Syndrome

E25 Adrenogenital disorders: Macrogenitomy in boys; Adrenogenital syndrome; Decreased function of the sex glands; Congenital dysfunction of the adrenal cortex; Apera-Halle Syndrome; Crook-Apera-Halle Syndrome

N91 Absence of menstruation, meager and rare menstruation: Amenorrhea; Amenorrhea hypogonadotropic; Amenorrhea is prolactin-dependent; Oligomenorrhoea; Shortening of the secretory phase of the menstrual cycle; Menstrual disorders; Menstruation disorders; Prolactin-dependent amenorrhea without galactorrhea

N97 Female infertility: Female infertility in anovulation; Hyperprolactinemic infertility; Hyperprolactinaemia with infertility; Endocrine infertility; Infertility due to hypothalamic-pituitary dysfunction; Infertility infertility; Infertility; Infertility on the background of hyperprolactinaemia; Functional infertility; Marriage is infertile; Infertility of ovarian genesis; Stimulation of the growth of a single follicle

O92.6 Galactorrhea: Chiari-Frommel Syndrome; Idiopathic galactorrhea

Composition

Tablets - 1 table.

active substance: Abergin® (bromocriptine mesylate) in terms of 100% material 0.004 g

Auxiliary substances: lactose (milk sugar); potato starch; Citric acid; Disodium edetate (EDTA disodium salt); Silicon dioxide colloid (aerosil A380); Methylparahydroxybenzoate (nipagine); Magnesium stearate (magnesium stearic acid) - a sufficient amount to obtain a tablet weighing 0.14 g

Pharmachologic effect

Mode of action - antiparkinsonian, dopaminomimetic.

Dosing and Administration

Inside, with food.

Abergin® is taken according to the following scheme: at the beginning of treatment, according to table 1/2. 2-3 times a day, then increase the dose by 1/4 table. Every 1-2 days, bringing up to 3-4 tablets. Per day for hyperprolactinemic states (under the control of blood prolactin level) and up to 5-6 tablets. Per day with acromegaly (under the control of the content in the blood of growth hormone and prolactin). The maximum daily dose for acromegaly in some cases can reach 10 tablets. The duration of administration and dose of the drug are determined by the doctor depending on the clinical situation.

Release form

Tablets of 4 mg. For 10 tablets in a planar cell pack. For 30 tablets in a can of orange glass, ukuporennoy cover. 1 or 3 contour packs, or a can in a pack of cardboard.

Manufacturer

ZAO "Pharmcenter VILAR"

Terms of leave from pharmacies

On prescription.

Storage conditions of the drug Abergin

In a dry, the dark place at a temperature of no higher than 5 ° C.

Keep out of the reach of children.

Shelf life of the drug Abergin

3 years.

Do not use after the expiry date printed on the package.